RhumbLine Advisers’s Starling Oncology STLN Stock Holding History

RhumbLine Advisers’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-77,845	Closed	-$239K	–	4256
2026 Q1	$239K	Buy	77,845 +3,260	+4%	+$10K	﹤0.01%	3037
2025 Q4	$266K	Sell	74,585 -8,794	-11%	-$32.6K	﹤0.01%	3037
2025 Q3	$291K	Sell	83,379 -1,852	-2%	-$6.35K	﹤0.01%	3020
2025 Q2	$175K	Buy	+85,231	New	+$213K	﹤0.01%	3303
2024 Q3	–	Sell	-2,175	Closed	-$1K	–	4327
2024 Q2	$1K	Hold	2,175	–	–	﹤0.01%	4244
2024 Q1	$3.44K	Hold	2,175	–	–	﹤0.01%	4032
2023 Q4	$4.44K	Hold	2,175	–	–	﹤0.01%	4004
2023 Q3	$3.04K	Sell	2,175 -10,037	-82%	-$10.4K	﹤0.01%	4061
2023 Q2	$6.72K	Sell	12,212 -26,388	-68%	-$14K	﹤0.01%	4032
2023 Q1	$26K	Buy	38,600 +1,818	+5%	+$2.32K	﹤0.01%	2930
2022 Q4	$61K	Buy	36,782 +1,154	+3%	+$3.24K	﹤0.01%	2945
2022 Q3	$165K	Buy	35,628 +13,141	+58%	+$77.3K	﹤0.01%	2932
2022 Q2	$114K	Buy	+22,487	New	+$164K	﹤0.01%	3023

Other funds holding STLN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

RhumbLine Advisers's STLN Position: Q2 2026 in Review

RhumbLine Advisers sold out of Starling Oncology (STLN) in Q2 2026, closing a stake of 77,845 shares — an estimated $239K sold.

RhumbLine Advisers first reported a position in STLN in Q2 2022 and held it in 13 quarters. The position peaked at $291K in Q3 2025. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

RhumbLine Advisers reported no remaining Starling Oncology position as of Q2 2026 after selling out during the quarter.
RhumbLine Advisers sold 77,845 Starling Oncology shares in Q2 2026, an estimated $239K.
RhumbLine Advisers first reported a position in Starling Oncology in Q2 2022 and held it in 13 quarters.
RhumbLine Advisers's Starling Oncology position peaked at $291K in Q3 2025.
119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.